Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood

There is mounting evidence that the gut microbiota plays an important role in the pathogenesis of inflammatory bowel disease (IBD). For the past decade, high throughput sequencing-based gut microbiome research has identified characteristic shifts in the composition of the intestinal microbiota in pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Adi Eindor-Abarbanel, Genelle R. Healey, Kevan Jacobson
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	IBD microbiome microbiome modulation EEN prebiotics dietary fibre Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/830a4db2013047eb9e6d8eff637f5c2e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:830a4db2013047eb9e6d8eff637f5c2e
record_format	dspace
spelling	oai:doaj.org-article:830a4db2013047eb9e6d8eff637f5c2e2021-11-25T17:57:20ZTherapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood10.3390/ijms2222125061422-00671661-6596https://doaj.org/article/830a4db2013047eb9e6d8eff637f5c2e2021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12506https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067There is mounting evidence that the gut microbiota plays an important role in the pathogenesis of inflammatory bowel disease (IBD). For the past decade, high throughput sequencing-based gut microbiome research has identified characteristic shifts in the composition of the intestinal microbiota in patients with IBD, suggesting that IBD results from alterations in the interactions between intestinal microbes and the host’s mucosal immune system. These studies have been the impetus for the development of new therapeutic approaches targeting the gut microbiome, such as nutritional therapies, probiotics, fecal microbiota transplant and beneficial metabolic derivatives. Innovative technologies can further our understanding of the role the microbiome plays as well as help to evaluate how the different approaches in microbiome modulation impact clinical responses in adult and pediatric patients. In this review, we highlight important microbiome studies in patients with IBD and their response to different microbiome modulation therapies, and describe the differences in therapeutic response between pediatric and adult patient cohorts.Adi Eindor-AbarbanelGenelle R. HealeyKevan JacobsonMDPI AGarticleIBDmicrobiomemicrobiome modulationEENprebioticsdietary fibreBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12506, p 12506 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	IBD microbiome microbiome modulation EEN prebiotics dietary fibre Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	IBD microbiome microbiome modulation EEN prebiotics dietary fibre Biology (General) QH301-705.5 Chemistry QD1-999 Adi Eindor-Abarbanel Genelle R. Healey Kevan Jacobson Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood
description	There is mounting evidence that the gut microbiota plays an important role in the pathogenesis of inflammatory bowel disease (IBD). For the past decade, high throughput sequencing-based gut microbiome research has identified characteristic shifts in the composition of the intestinal microbiota in patients with IBD, suggesting that IBD results from alterations in the interactions between intestinal microbes and the host’s mucosal immune system. These studies have been the impetus for the development of new therapeutic approaches targeting the gut microbiome, such as nutritional therapies, probiotics, fecal microbiota transplant and beneficial metabolic derivatives. Innovative technologies can further our understanding of the role the microbiome plays as well as help to evaluate how the different approaches in microbiome modulation impact clinical responses in adult and pediatric patients. In this review, we highlight important microbiome studies in patients with IBD and their response to different microbiome modulation therapies, and describe the differences in therapeutic response between pediatric and adult patient cohorts.
format	article
author	Adi Eindor-Abarbanel Genelle R. Healey Kevan Jacobson
author_facet	Adi Eindor-Abarbanel Genelle R. Healey Kevan Jacobson
author_sort	Adi Eindor-Abarbanel
title	Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood
title_short	Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood
title_full	Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood
title_fullStr	Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood
title_full_unstemmed	Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood
title_sort	therapeutic advances in gut microbiome modulation in patients with inflammatory bowel disease from pediatrics to adulthood
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/830a4db2013047eb9e6d8eff637f5c2e
work_keys_str_mv	AT adieindorabarbanel therapeuticadvancesingutmicrobiomemodulationinpatientswithinflammatoryboweldiseasefrompediatricstoadulthood AT genellerhealey therapeuticadvancesingutmicrobiomemodulationinpatientswithinflammatoryboweldiseasefrompediatricstoadulthood AT kevanjacobson therapeuticadvancesingutmicrobiomemodulationinpatientswithinflammatoryboweldiseasefrompediatricstoadulthood
_version_	1718411813814534144

Therapeutic Advances in Gut Microbiome Modulation in Patients with Inflammatory Bowel Disease from Pediatrics to Adulthood

Ejemplares similares